home / stock / alim / alim news

ALIM News and Press, Alimera Sciences Inc. From 03/31/23

Stock Information
Company Name: Alimera Sciences Inc.
Stock Symbol: ALIM
Market: NASDAQ
Website: alimerasciences.com
Menu
ALIM ALIM Quote ALIM Short ALIM News ALIM Articles ALIM Message Board
Get ALIM Alerts

News, Short Squeeze, Breakout and More Instantly...
ALIM - Alimera Sciences Announces 2022 Financial Results and Business Update

• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 • Global End User Demand Increased 22% over 2021 to 9,266 Units • Strengthened Balance Sheet, Repurchased Stock and Extended Term Loan Facility ATLANTA, March 31, 2023 (GLOBE NEWSW...
ALIM - Alimera Sciences Q4 2022 Earnings Preview

2023-03-30 12:50:53 ET Alimera Sciences ( NASDAQ: ALIM ) is scheduled to announce Q4 earnings results on Friday, March 31th, before market open. The consensus EPS Estimate is -$0.48 (+18.6% Y/Y) and the consensus Revenue Estimate is $14.62M (+4.8% Y/Y). For further d...

ALIM - AAOI, CMPR and WISA among mid-day movers

2023-03-27 13:06:40 ET Gainers: WiSA Technologies ( WISA ) +93% . First Citizens BancShares ( FCNCA ) +50% . Alimera Sciences ( ALIM ) +38% . Cimpress ( CMPR ) +30% . Gorilla Technology Group ( GRRR ) +25% . CBL International...

ALIM - NBRV, JNCE and ALIM among healthcare movers

2023-03-27 10:47:00 ET Gainers: Pyxis Oncology ( PYXS ) +25% . Delcath Systems DCTH +23% . Jounce Therapeutics ( JNCE ) +23% . Alimera Sciences ( ALIM ) +22% . Coeptis Therapeutics ( COEP ) +21% . Losers: Unity Biotechnology ...
ALIM - Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility

Repurchases Series A Preferred Stock, eliminating $24 million liquidation preference for approximately $938,000 Completes $12 million private placement of preferred stock and warrants with conversion price and exercise price at 55% premium to the closing share price on March 24, 202...

ALIM - Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update

ATLANTA, March 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will repo...

ALIM - Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors

ATLANTA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces th...
ALIM - Alimera's partner files for approval of eye implant therapy Iluvien in Switzerland

Alimera Sciences ( NASDAQ: ALIM ) said its distribution partner Horus Pharma through its Swiss affiliate Horus Pharma Suisse filed a marketing authorization application (MAA) in Switzerland  for Iluvien to treat diabetic macular edema (DME). The Swiss application for consist...

ALIM - Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®

ATLANTA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that its...

ALIM - Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer

ATLANTA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced t...
Previous 10 Next 10